Vaccines

September 13, 2022

COVID-19 bivalent vaccine boosters available for employees of VUMC and VU, as well as patients

September 7, 2022

VUMC study will evaluate alternative strategies for administering mpox vaccine

Rarely fatal, the mpox virus — spread by close, often skin-to-skin contact — causes a painful, blistering rash, fever, chills and other symptoms.

The study team included (front row, from left) Kelsey Voss, PhD, Rachel Bonami, PhD, Erin Wilfong, MD, PhD, (back row, from left) Jonathan Irish, PhD, Jeff Rathmell, PhD, and Ivelin Georgiev, PhD.
July 20, 2022

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

June 16, 2022

VUMC research aids approval of COVID-19 vaccine for young children

The U.S. Food and Drug Administration is expected to authorize Pfizer and Moderna’s COVID-19 vaccines for children as young as 6 months old as early as tomorrow, following the unanimous recommendation by an FDA advisory panel on Wednesday.

June 1, 2022

RSV vaccine trial enrolling 6- to 24-months-old children

May 19, 2022

Panel considers ways to improve vaccine readiness, restore trust

A recent Ethics Grand Rounds, sponsored by the Vanderbilt Center for Biomedical Ethics and Society, explored potential ways to overcome vaccine readiness and restore trust in health care providers.